The 24 references in paper N. Zagidullin Sh., R. Zulkarneev Kh., Yu. Safina F., Yu. Aznabaeva G., Sh. Zagidullin Z., Н. Загидуллин Ш., Р. Зулкарнеев Х., Ю. Сафина Ф., Ю. Азнабаева Г., Ш. Загидуллин З. (2016) “Влияние комбинированной терапии индакатеролом и гликопиррония бромидом на состояние респираторной и сердечно-сосудистой систем у пациентов с хронической обструктивной болезнью легких // Respiratory and cardiovascular effects of combined therapy with indacaterol and glycopyrronium bromide in chronic obstructive pulmonary disease” / spz:neicon:pulmonology:y:2015:i:6:p:747-752

1
Global Initiative for Chronic Obstructive Lung Disease (2013) Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. www.goldcopd.com
(check this in PDF content)
2
Beeh K.M., Beier J. Indacaterol: a new once daily long-acting beta2-adrenoceptor agonist. Core Evidence. 2009; 4: 37–41.
(check this in PDF content)
3
Feldman G., Siler T, Prasad N. et al. Efficacy and safety of indacaterol 150 microg once-daily in COPD: a double-blind, randomised, 12-week study. BMC Pulm. Med.2010; 10: 11.
(check this in PDF content)
4
Chapman K.R., Rennard S.I., Dogra A. et al. Long-term safety and efficacy of indacaterol, a long-acting β2-agonist, in subjects with COPD: a randomized, placebo-controlled study. Chest. 2011; 140 (1): 68–75.
(check this in PDF content)
5
Dahl R., Chung K.F., Buhl R. et al. Efficacy of a new once daily long-acting inhaled β2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax. 2010; 65: 473–479.
(check this in PDF content)
6
Buhl R., Banerji D. Profile of glycopyrronium for oncedaily treatment of moderate-to-severe COPD. Int. J. COPD.2012; 7: 729–741.
(check this in PDF content)
7
Ulrik C.S. Once-daily glycopyrronium bromide, a long-acting muscarinic antagonist, for chronic obstructive pulmonary disease: a systematic review of clinical benefit. Int. J. COPD.2012; 7: 673–678.
(check this in PDF content)
8
Barnes P.J. Anticholinergic Therapy in Obstructive Airway Disease. Ed. by N.Gross.London; 1993: 88–104.
(check this in PDF content)
9
Brown J.H., Taylor P. Goodman and Gilman’s the Pharmacological Basis of Therapeutics. Ed. by J.G. Hardman et al. New York; 1996: 141.
(check this in PDF content)
10
Lange P., Mogelvang R., Marott J.L. et al. Cardiovascular morbidity in COPD: a study of the general population. COPD. 2010; 7: 5–10.
(check this in PDF content)
11
Konecny T., Park J.Y., Somers K.R. et al. Relation of chronic obstructive pulmonary disease to atrial and ventricular arrhythmias.Am. J. Cardiol.2014; 15: 114 (2): 272–277.
(check this in PDF content)
12
Zulkarneev R., Zagidullin N., Abdrahmanova G. et al. Ivabradine prevents heart rate acceleration in patients with chronic obstructive pulmonary disease and coronary heart disease after salbutamol inhalation. Pharmaceuticals. 2012; 5 (4): 398–404.
(check this in PDF content)
13
Hanrahan J.P., Grogan D.R., Baumgartner R.A. et al. Arrhythmias in patients with chronic obstructive pulmonary disease (COPD): occurrence frequency and the effect of treatment with the inhaled long-acting beta2-agonists arformoterol and salmeterol. Medicine(Baltimore). 2008; 87 (6): 319–328.
(check this in PDF content)
14
Karvandi M., Piranfar M.A., Ghaffaripour M. et al. An alternative method for perioperative estimation of pulmonary artery systolic pressure by echocardiography. Shiraz E*Med. J. 2007; 8: 4:174–182.
(check this in PDF content)
15
Curkendall S.M., DeLuise C., Jones J.K. et al. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann. Epidemiol.2006; 16: 63–70.
(check this in PDF content)
16
Schneider C., Bothner U., Jick S.S., Meier C.R. Chronic obstructive pulmonary disease and the risk of cardiovascular diseases.Eur. J. Epidemiol. 2010; 25: 253–260.
(check this in PDF content)
17
Roque A.L., Valenti V.E., Massetti T. et al. Chronic obstructive pulmonary disease and heart rate variability: a literature update. Int. Arch. Med.2014; 3 (7): 43.
(check this in PDF content)
18
Forfia P.R., Fisher M.R., Mathai S.C. et al. Tricuspid annular displacement predicts survival in pulmonary hypertension. Am. J. Respir. Crit. Care Med.2006; 174 (9): 1034–1041.
(check this in PDF content)
19
Worth H., Fan Chung K., Felser K. et al. Cardio- and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD.Respir. Med.2011; 105: 571–579.
(check this in PDF content)
20
Bateman E., Ferguson G.T., Barnes N. et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study.Eur. Respir. J. 2013; 42: 1484–1494.
(check this in PDF content)
21
Mahler D., Decramer M., D’Urzo A. et al. Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE study. Eur. Respir. J. 2014; 43: 1599–1609.
(check this in PDF content)
22
Wedzicha J., Decramer M., Ficker J.H. et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, doubleblind, parallel-group study. The Lancet. Lancet Respir. Med. 2013; 1 (3): 199–209.
(check this in PDF content)
23
Zhong N., Wang C., Zhou W. LANTERN: a randomized study of QVa149 versus salmeterol / fluticasone combination in patients with COPD. Int. J. COPD.2015; 10: 1015–1026. Поступила 18.12.15 УДК 616.246036.126085.236092 Received December 18, 2015 UDC 616.246036.126085.236092 Информация об авторах Загидуллин Науфаль Шамилевич– д. м. н., доцент, профессор кафедры пропедевтики внутренних болезней ГБОУ ВПО «Башкирский государственный медицинский университет» Минздрава России; тел.: (347) 246-53-97; e-mail: znaufal@mail.ru Сафина Юлиана Фадисовна– аспирант кафедры пропедевтики внутренних болезней ГБОУ ВПО «Башкирский государственный медицинский университет» Минздрава России; тел.: (347) 246-53-97; e-mail: y.f.safina@mail.ru Зулкарнеев Рустем Халитович– д. м.
(check this in PDF content)
24
53-97; e-mail: zshamil@inbox.ru Author information Zagidullin Naufal' Shamilevich,MD, Assistant Professor, Professor at Department of Propaedeutics of Internal Diseases, Bashkir State Medical University, Healthcare Ministry of Russia; tel.: (347) 246-53-97;
(check this in PDF content)